StemCell Therapy

HIGH POINT, N.C., Aug. 14, 2020 Members of the High Point University community frequently conduct, publish and share research and creative works in a variety of ways. Below is a recap of recent research initiatives.

HPU Student, Alumna and Faculty Research Featured in National Scientific Journal

Casey Garr, HPU alumna; Candyce Sturgeon, HPU rising senior; Dr. Veronica Segarra, HPU assistant professor of biology; and Noah Franks, student at Penn Griffin School of the Arts in High Point, North Carolina; recently conducted research that was published in Autophagy, a national scientific journal.

The study, titled, Autophagy as an on-ramp to scientific discovery, examines HPUs Cell Art Collaborative program to gain understanding around how the recruitment of highly creative students into STEM fields through connections to art can be a first step in defining a specialized career path that leads to a valuable and unique contribution to science.

In addition to providing experiential learning opportunities for students at HPU to conduct hands-on research and co-author peer-reviewed articles, the Cell Art Collaborative program encourages students in the local community to explore careers that incorporate both science and art, says Segarra. This initiative continues to facilitate conversations around STEAM-based learning environments for educators to take advantage of a wider range of student talents and interests, preparing them to go forth into society as the creative thinkers and problem solvers the world needs.

HPU Students Research Featured in CBE: Life Sciences Education Journal

Clara Primus, a rising junior majoring in biology and Bonner Leader at HPU, recently collaborated with prominent scientists at the Mayo Clinic, University of California Davis and Northwestern to conduct research that was published in CBE: Life Sciences Education, a quarterly journal published by the American Society for Cell Biology. The article, titled, Scientific Societies Fostering Inclusive Scientific Environments through Travel Awards: Current Practices and Recommendations, examines how scientific societies can contribute to a diverse and inclusive workforce.

The research compares and contrasts the broad approaches that scientific societies within the National Science Foundation-funded Alliance to Catalyze Change for Equity in STEM Success (ACCESS) use to implement and assess their travel award programs for underrepresented minority (URM) trainees. Findings will improve collaboration and better position scientific societies to begin addressing some of these questions and learning from each other.

The recommendations included in this research shed light on how even scientific societies can be allies in furthering inclusion efforts, said Primus. Ive spent nearly two years studying equity and diversity, and I hope that I can take the knowledge Ive learned from all of my research to educate my peers at HPU.

HPU Exercise Science Professor Publishes Statement for the American Heart Association

Dr. Colin Carriker, assistant professor of exercise science in HPUs Congdon School of Health Sciences, recently co-authored an American Heart Association (AHA) scientific statement on medicinal and recreational cannabis use published in Circulation.

The statement critically reviews the use of medicinal and recreational cannabis from a clinical but also a policy and public health perspective by evaluating its safety and efficacy profile, particularly in relation to cardiovascular health. The purpose of this scientific statement was to explore the evidence and science pertaining to medical marijuana, recreational cannabis and cardiovascular health to provide physicians and health care providers with the information available to date. While cannabis may have some therapeutic benefits, these do not appear to be cardiovascular in nature. Health care providers would benefit from increased knowledge, education and training pertaining to various cannabis products and health implications, including recognition that cannabis use may, in fact, exacerbate cardiovascular events or other health problems. In this regard, the negative health implications of cannabis should be formally and consistently emphasized in policy, while aligning with the American Heart Associations commitment to minimizing the smoking and vaping of any products and banning cannabis use for youth.

It was an honor to work alongside such a high-quality team of researchers, says Carriker. I want to especially thank our committee chairs, Dr. Robert L. Page II and Dr. Larry A. Allen, as their extraordinary leadership and organization were integral components in the completion and publication of this AHA scientific statement. We publish these statements to counterbalance and debunk misinformation because the public requires high-quality information about cannabis from reputable organizations such as the American Heart Association.

Carriker is the advocacy ambassador for the American Heart Associations Council on Lifestyle and Cardiometabolic Health and served as a member of the writing committee tasked with writing this AHA Scientific Statement initiated by the AHAs Council on Clinical Cardiology.

Go here to read the rest:
HPU Students, Faculty and Staff Recognized for Research and Innovation - High Point University

STATEMENT BY PREMIER AND MINISTER OF FINANCEHONOURABLE ANDREW A. FAHIE

COVID-19 UPDATE- PHASE II

Friday, 14th August, 2020

I say good day and Gods Blessings to all the people of the Virgin Islands.

We thank the Lord our God for his continued blessings in our lives and in our Territory.

The world continues to grapple with the realities of COVID-19 and the BVI, is not immune.

I appreciate what we continue to do together in our little corner of the world to keep ourselves and each other safe.

So far we have only had nine confirmed cases, including one death with 8 recoveriesmost of the cases being classified as imported or related.

Together, we have been able to stem the tide, but we are not out of the woods.

The problem of COVID-19 has not yet been solved.

It remains a real, deadly, imminent threat to all persons in all countries throughout the world.

We continue to see countries rushing forward with haste to open their borders, refusing to close their borders, or disobeying the recommended hygiene and safety protocols, only for them to hastily retreat as they experience a surge of infections in their population.

Can I tell you that right now, the only measures that are scientifically proven to keep us all safe are social distancing, wearing of appropriate masks or shield, and washing our hands regularly?

These measures are simple for us to do, so let us continue to do them.

In all our actions, your Government is being guided by the law, international protocols and international best practice, with guidance from God Almighty.

In particular, we are being guided by the provisions of the Public Health Ordinance, the Quarantine Act and the Infectious Diseases (Notification) Act, all of which are designed to treat with circumstances such as these, and which prescribes measures that should be taken whenever there is the risk of an outbreak of disease.

All of our precautionary measures for protecting our people from the public health threat of COVID-19 are soundly grounded in the law of the land. And, your Government is being very cautious in dealing with this very fluid situation because another round of lockdown can cripple our economy to the point that we may not be able to bounce back.

Indeed, we understand and empathise with the inconvenience and hardship that COVID-19 is causing to everyone; however we must be cognisant of the double-threat to public health and the economy.

In the BVI, we cannot afford another lockdown. It will not be healthy for our economy, economically, socially and healthwise.

We are not immuned to the trickled effect of COVID-19, which is a health issue.

That is why even with the controlled re-entry of Virgin Islands, Belongers, permanent residence and Naturalisaed Overseas Territories citizens, since 2 June 2020 and the full internal re-opening of businesses, we have been moving cautiously, and in a phased way so that we can realistically manage our environment and surroundings in the midst of the New Regular of living and working with COVID-19.

There have been several views from many quarters trying to pressure the Government to open up quickly and to open up now.

But, I want to echo something that the Chief Medical Officer Dr. Irad Potter said to Members of Cabinet, which I think was the most profound statement that caused all of us to pause, he said and I quote,

We must take into consideration what risk we can take. We must take into consideration what risk we can manage. And, we must take into consideration what we can and cannot allow. End of quote.

Your Government intends to concentrate on the areas that united us as a people because only through unity will we get through this pandemic, successfully.

To date we have been able to manage and monitor the process to the point where on behalf of the Cabinet of the Virgin Islands, I can now announce that we are now moving into Phase two of our Restricted Border Re-opening Plan.

We are satisfied that the different Government agencies have the necessary protocols in place as we advance into Phase two of the restricted border controlled process.

We have had Special meetings of the Cabinet on 13th August and we had to continue the meeting on 14th August. These are not easy decisions, as checks and balances are important.

But having been satisfied that we have properly ventilated and learn from lessons in Phase one to strengthen Phase two, on behalf of Cabinet, I wish to make the following announcements:

1. We decided that the Ministry of Health and Social Development instruct the Attorney General's Chambers to draft a new Immigration and Prohibition Order for the period from 15th August, 2020 to 31st August, 2020;

People of the Virgin Islands Cabinet also advised that the National Security Council should not extend the Curfew Order, which expired on 13th August, 2020, thereby re-opening the Territory internally for 24-hours a day, seven days a week.

However, all businesses and individuals must adhere to all of the approved social measures; and Cabinet also advised that the National Security Council will impose restrictions on the movement of vessels within Territorial waters in a manner prescribed by Order.

Let me say here.

We are not out of the woods with COVID-19. People are coming in, in phase one and two.

We must continue to remain vigilant.

We cannot leave any stone unturned with COVID-19.

That is why the social distancing measures must apply. That is why adherence to the health protocol is a must.

This is our opportunity to test the strength of our system, our protocol, our preventative measures and our commitment to a healthy and safe Virgin Islands.

If we all follow the rules, all will be well.

I want to take this time to remind our bikers those on the scoters, all our bikers, that safe riding save lives. Please ensure that you have a scooter licence, ensure that your motorbikes are licensed and insured, always wear a helmet, know your scooters limits, watch your speed, keep your distance from other vehicles, use both brakes, avoid blind spots, always use signals. Our young generation is important to the future of this Territory. When our youth damage themselves, they damage their future potential in the Virgin Islands. Remember Your Life Matters!

Our responsibility as a Government is to keep the people of the Virgin Islands healthy and safe as much is humanly possible during this COVID-19 era and at all times.

I want to thank everyone who continues to help us to be safe during this COVID-19 era.

My Government, Cabinet Members, National Security Council, Attorney General Chambers, Cabinet Office, all Members of the House of Assembly, the Health Emergency Operations Centre, the Government public officers at varying levels, the Joint Information Cell/Government Information Service, industry partners and members of the public for all coming together and doing their part in this fight against COVID-19.

In these Virgin Islands, each of us has a role to play to help our economy and to keep us safe.

Remember we are all in this together, but I must warn again that we are not out of the woods as far as COVID-19 is concerned.

Remember that COVID-19 is not playing around with us and we must not play around with COVID-19

Now that the curfew is lifted, more than ever, and the borders remain closed, with limited entry, we must hold each other accountable to get through this experience together.

This phase is our greatest test and I know with Gods help we will pass this test.

Please be advised that the main point of entry remains the TB Lettsome International Airport.

So, let us continue to work together in the oneness of purpose.

Remember, God is with us, and He is opening doors for us so that we can have a Virgin Islands that generations would be proud of.

As leader of Government business, we will continue to keep you the people informed of our efforts to continue to combat COVID-19 as this remains a fluid situation. We will continue to make adjustments, so that the people of the Virgin Islands will remain safe while we balance our economy starting with the rebooting and the revitalization of our internal economy.

May God continue to bless these beautiful Virgin Islands and the people of the Virgin Islands.

I thank you.

Read more here:
Statement By Premier Fahie On COVID-19 Update - Phase II - Government of the Virgin Islands

No matter what type of diabetes you have, the goal of diabetes treatment is to control blood sugars and keep them within the healthy range.

Type 1 diabetes must be treated with insulin, since the pancreas does not produce insulin naturally. People with type 2 or gestational diabetes don't always need insulin treatment, and will often focus on lifestyle changes and oral medications that encourage insulin production or decrease insulin resistance.

With proper access to healthcare, diabetes is highly treatable, says Katherine Araque, MD, an endocrinologist and director of endocrinology of the Pacific Neuroscience Institute at Providence Saint John's Health Center in Santa Monica, California.

Here are the four main ways you can treat and manage your diabetes.

Insulin is a hormone produced in the pancreas in healthy individuals. It helps facilitate the process of converting blood sugar into fuel, so that glucose doesn't build up in the blood.

In people with type 1 diabetes, the pancreas cannot produce insulin, so they need synthetic insulin. This can happen in two ways:

People with type 2 diabetes are treated with insulin when they are unable to control their blood glucose levels with lifestyle changes and medication. Overall, roughly 24% of people with diabetes are treated with insulin, according to a 2018 study published in Diabetes Care.

If you need insulin, your doctor will provide specific guidance on how much you need and when you should take it.

Although people with type 1 diabetes will need insulin, they may also be prescribed medication if they have some remaining pancreas function. The medication can encourage insulin production in the body.

People with type 2 diabetes are prescribed medication when they can't control their blood sugars through diet and exercise. Oftentimes, people with type 2 diabetes use more than one medication to control their condition.

However, medications are usually not recommended for pregnant people with gestational diabetes.

Common medications used to treat diabetes include:

Metformin is the most common medication used to treat type 2 diabetes. It's sometimes used to treat type 1 diabetes in people who still have some insulin production, along with insulin.

Metformin helps control blood sugar by making it easier for the body to absorb glucose. It's usually taken twice a day, with meals. Even when used alone, metformin can reduce A1C levels by 1.5% on average, which is enough to drop blood sugar levels from diabetes to prediabetes.

Sulfonylureas are a class of drugs that encourage the pancreas to release more insulin. They're used to treat type 2 diabetes. They are often taken once or twice a day before meals.

Sulfonylureas have a similar efficacy to metformin, and can be used alongside it.

TZDs make it easier for the body to use insulin; they reduce insulin resistance. They can be used to treat type 2 diabetes. They are taken 1 to 2 times per day.

After a year of taking TZDs, people with type 2 diabetes reduced their A1C levels by 1.4%, according to a 2019 study published in Vascular Health Risk Management.

Exercise is important for people with all types of diabetes. "Exercise helps at multiple levels: it increases base metabolic rate, fights insulin resistance, and helps with weight loss," says Araque.

Exercise helps muscles burn glucose and reduces insulin resistance. When you exercise, your muscles burn more glucose, removing it from the bloodstream and helping to lower blood sugar levels.

For example, a 2017 study published in Biomedical Research followed 120 obese teens, who did two hours of aerobic exercise twice a day for six days a week. After five weeks, their average fasting blood sugar was reduced by 0.84 nanomoles per liter (nmol/L) for males and 1.04 nmol/L for females. The researchers described this as "an extremely significant difference."

The Center for Disease Control and Prevention (CDC) recommends that people with diabetes get the normally recommended amount of exercise: 150 minutes of exercise each week, including two days of strength workouts that incorporate major muscle groups. The American Diabetes Association recommends starting with small changes, like walking daily.

Any exercise will help, but some may be especially beneficial. For example, a 2019 study published in Diabetologia found that afternoon exercise decreased blood sugars more than morning exercise.

Overall, you should work with your doctor to identify an exercise program that will benefit you, Araque says.

Healthy eating is critical for people with diabetes. As food breaks down, it releases glucose into your blood. Some foods, including processed sugars and carbohydrates, raise blood sugars more than other foods, like proteins or leafy vegetables.

In particular, people with diabetes need to be aware of how many carbs they eat per day. They should also create an eating plan that includes the following:

For example, the DASH diet and Mediterranean diet which both emphasize healthy fats, lean protein, protein and vegetables have been proven to help people with type 1 and type 2 diabetes control blood sugar.

Read more about the best ways to eat if you have diabetes:

Diabetes is a chronic but manageable condition, Araque says. People with diabetes should work with their doctor, nutritionist, and an exercise professional to design a program that meets their needs.

"The most important message is if they follow these recommendations they can get this under control and decrease risk for complications," Araque says. "Patients should have hope."

Read the original post:
4 of the best ways to treat diabetes and lower blood sugar - Insider - INSIDER

Recent research in the Journal of Medicine (2016) has shown us that rates of depression can be twice as high in people with type 2 diabetes than in the general population. So, whats the missing link here? Why do people with diabetes tend to experience more issues with depression?

To start, the Stand American Diet is closely tied to the development of T2D. In a study published in 2017, people who regularly consumed red meat, processed meat, sugar sweet beverages (SSB), and eggs showed to have two times the risk of T2D. Also, people who added to their diet whole grains, vegetables, fruits, and dairy showed a 42% reduction compared to the prior group. Perhaps most amazing in this study is that people who combined both not eating the unhealthy foods and adding in the healthy foods, showed a whopping total risk reduction of 70%! (European Journal of Epidemiology).

Now, consider that studies have also shown that the Standard American Diet is tied to depression. High consumption of red and/or processed meat, refined grains, sweets, high-fat dairy products, butter, potatoes and high-fat gravy, and low intakes of fruits and vegetables is associated with an increased risk of depression (Psychiatry Research 2017). Alcohol, as well, can play a part given that increased use has shown an increased risk of depression (Addiction 2011). Epidemiological evidence suggests a strong connection between diet quality and mental health across multiple populations and age groups (the Nutrition Society 2017).

Diabetes is a chronic health condition that prevents insulin from allowing glucose into muscle cells in the body. Glucose (a monosaccharide sugar) is the major energy source of the body. People with type two diabetes (T2D) cannot properly use the insulin their bodies make, resulting in too much glucose circulating in the bloodstream. Over time, this can cause serious health problems. In 1958, less than one percent of the U.S. had diabetes. By 2019, that number had grown to 13% a 1200% increase!

It has also been suggested that the effect of exercise also may be comparable to antidepressant medication and psychotherapy for mild to moderate depression. As well, exercise seems to be a valuable complementary therapy to the traditional treatments for severe depression (Disability Rehabilitation, 2015). Other studies have also shown that unhealth eating habits along with tobacco smoking and lower levels of physical activity are major contributors to chronic disease and mortality (Schizophrenia Research, 2018).

What all of this tells us that the missing link between depression and type 2 diabetes is something we actually have some control over. Simply lifestyle choices that we can make can prevent the majority of T2D and have profound effects on depression symptoms. Eating a healthy diet, not smoking, low consumption of alcohol, and moderate exercise can reduce the risk of T2D by 91% (New England Journal of Medicine). Changing what we eat can actually provide a clinically significant benefit to traditional forms of treatment for both diabetes and depression.

Jim Runnels is a retired Licensed Professional Counselor and advocate of evidence-based education and supporter of the health benefits of a whole food plant-based, active lifestyle, to achieve optimal health. He is the administrator of Eat Healthy-Texoma Facebook page. The views and opinions expressed here are the authors own and do not necessarily reflect those of the Herald Democrat.

Here is the original post:
MENTAL HEALTH MATTERS: Depression and diabetes: Are they linked? - Sherman Denison Herald Democrat

Diabetes increases the risk of kidney cancer in postmenopausal women, but paradoxically, only in nonobese women, as defined by body mass index (BMI) and waist circumference, according to a new analysisfrom the Iowa Women's Health Study (IWHS).

"Many studies have linked a history of diabetes to the increased risk of kidney cancer [but] it is unclear whether diabetes is a risk factor for kidney cancer independent of other risk factors such as obesity and hypertension," write Shuo Wang, PhD, of the School of Public Health, University of Minnesota, Minneapolis, and colleagues.

"[While we found that] an association between diabetes and kidney cancer was not statistically significant among the whole cohort...a positive, statistically significant association was observed among nonobese women (BMI < 30 kg/m2) or waist circumference < 34.6 inches (87.9 cm)," the authors suggest.

And although they acknowledge "these findings should be validated in larger or pooled prospective studies," they stress that "patients with new-onset diabetes may require more thorough surveillance for cancer including kidney cancer."

The results were published online August 11 in Maturitas.

The IWHS was launched in 1986 when a baseline questionnaire was completed by a total of 41,836 women.

Subsequent questionnaires were mailed in 1987, 1989, 1992, 1997, and 2004, returned by increasingly fewer respondents over the years.

The cohort for the current analysis included 36,975 women, mean age of 61.7 years, 6.4% of whom reported adiabetes diagnosisat baseline.

"At baseline, diabetes status was determined for each participant by one of two ways," the researchers explain.

Women were first asked if a physician had ever told them they had diabetes and were also asked whether they took pills for diabetes and/or insulin. A tape measure was included with the baseline questionnaire and women were asked to have their waist measured in a precise manner with a high degree of accuracy and reliability.

Between 1986 and 2011, investigators identified 257 cases of kidney cancer in their cohort.

They then examined the association between baseline and time-dependent diabetes and kidney cancer risk using three models, the first adjusted only for age, the second adjusted for age and BMI tertile, and the third was a multivariable-adjusted model.

The adjusted variables in the third model included age and indices of obesity, as reflected by BMI and waist-to-hip ratio (WHR), as well as physical activity levels, pack-years of smoking, total caloric intake, presence of hypertension, diuretic use, and alcohol intake.

Cutoffs used to define obesity included a BMI of 30 kg/m2, a WHR of 0.85, and a waist circumference of 34.6 inches.

Researchers also analyzed the association between duration of diabetes and kidney cancer risk using a nested-case control design within the IWHS cohort.

Over the course of follow-up, an additional 8.5% of women reported a new diagnosis of diabetes.

"Several characteristics were statistically significantly associated with kidney cancer risk," the authors note (Table 1).

"And time-dependent diabetes was associated with an increased risk of kidney cancer in models 1 and 2," they added.

Table 1. Increased Kidney Cancer Risk, Baseline Characteristics (Models 1, 2)

*4 grams/day of alcohol

BMI = body mass index; WHR = waist-hip ratio

However, when investigators adjusted the association between time-dependent diabetes and kidney cancer risk in model 3, associations seen in models 1 and 2 were attenuated and no longer significant, the authors underscore.

In contrast, the risk of kidney cancer increased for women with diabetes.

Compared to women without diabetes, women with diabetes and a BMI < 30 kg/m2 had an 82% higher risk of kidney cancer, and those with diabetes and a waist circumference < 34.6 inches had an over twofold greater risk (Table 2).

Table 2. Interaction Between Diabetes, Weight in Kidney CaRisk (Model 3)

BMI = body mass index; HR = hazard ratio; WC = waist circumference

As the investigators point out, there are a number of possible explanations for these seemingly paradoxical findings.

Type 2 diabetes is associated with high blood glucose, which itself may increase uncontrolled cell growth and division.

This may help explain why investigators saw a stronger association with kidney cancer among those with a shorter diabetes duration, that is, "those who are more likely to have uncontrolled diabetes," they explain.

Investigators also point out: "Patients with type 2 diabetes (the majority of diabetes cases in our study) have high serum levels of insulin that promote the secretion and production of insulin-like growth factor 1 (IGF-1)."

IGF-1 is important in the regulation of cell proliferation and differentiation, and thus may promote the formation and growth of cancer, they add.

But there is a "nonlinear relationship between BMI and IGF-1 levels," the investigators observe. For example, one study found that IGF-1 concentrations in women increased as BMI increased up to a maximum of 26 kg/m2, after which IGF-1 concentrations decreased among women with higher BMIs.

"In line with this finding, we found an association among nonobese women...even in the fully adjusted model, but observed no association between diabetes and kidney cancer among obese women...which could be explained by lower levels of IGF-1 among obese women."

Previous epidemiologic findings from the IWHS did find evidence of an association between weight-related measures and kidney cancer risk; however, those with a BMI in the top quartile had an almost 2.5-fold greater risk of kidney cancer than those in the lowest BMI quartile.

The study was funded by the National Cancer Institute. The authors have reported no relevant financial relationships.

Maturitas. Published online August 11, 2020. Abstract

For more diabetes and endocrinology news, follow us on Twitter and Facebook.

More here:
Diabetes Linked to Increased Kidney Cancer Risk, But Only in Slim - Medscape

If you have diabetes, your body isn't able to regulate blood sugar properly, either because the pancreas doesn't produce insulin (type 1 diabetes) or the body has become resistant to it (type 2 diabetes).

As a result, people with diabetes have to carefully manage their blood sugar levels through diet, exercise, and medications to make sure it stays in a healthy range.

But sometimes, blood sugar can become too high. In many of these cases, people with diabetes will be able to quickly lower blood sugar on their own, by taking more insulin. However, other times, they may need to visit the ER for immediate medical attention.

Here's how to tell if your blood sugar is too high and what you'll need to do in order to lower it quickly.

People with diabetes are considered to have high blood sugar, or hyperglycemia, if blood glucose levels are higher than:

While there are other conditions that can cause hyperglycemia, it is most commonly linked to both type 1 and type 2 diabetes. That's why it is important for people with diabetes to check their blood sugar using blood glucose meters with the goal of keeping levels from getting too low or too high.

In addition, there are other signs and symptoms of high blood sugar you might notice.

The most common symptoms of hyperglycemia are:

"If someone has hyperglycemia, it would mean they would be very thirsty, tired, they might be urinating more frequently and basically not feeling well," says Sam Zager, M.D. a family medicine physician in Maine.

Hyperglycemia is not automatically an emergent situation. Anyone with diabetes knows high blood sugar readings will happen, and it's okay, as long as it doesn't last too long or get too high.

If it does occur, here are a few ways to quickly lower blood sugar on your own:

Insulin can be used to treat acute cases of high blood sugar for people with diabetes.

People with type 1 diabetes (who always use insulin) and some people with type 2 diabetes (who sometimes use insulin) can give themselves an extra dose of insulin to quickly lower their blood sugar to safer levels. How much to take depends on the situation and what your doctor recommends.

When you have high blood sugar, you may experience frequent urination as your body tries to get rid of the extra glucose. Losing this fluid can cause dehydration and make hyperglycemia symptoms even worse.

It's important to drink water when you have hyperglycemia in order to stay hydrated and help your body regulate and lower blood sugar. But drinking lots of water won't necessarily lower blood sugar on its own. For more information, read about how much water you're supposed to drink a day.

Exercise isn't always the safest or most effective way to quickly lower blood sugar. It is important to note that exercise only works if there is insulin present, whether naturally or through injection, so that glucose can get into the cells to be metabolized.

If there is no insulin, your body will start burning fat for energy, and this could lead to a dangerous condition called diabetic ketoacidosis. People with type 1 diabetes should not exercise if they have hyperglycemia.

However, exercise can lower blood sugar for most people with diabetes it just shouldn't be used in emergency situations. In a 2013 study in the journal Diabetes Care, more than 5,000 people with diabetes recorded their blood glucose levels before and after exercising for as little as 10 minutes. Overall, more than 75% of people saw their level decrease an average of about 17%.

Overall, Zager says that exercise is important for managing diabetes, but warns that it isn't a great short-term fix. For more information on how to control blood sugars in the long-term, learn about the 6 best ways to lower blood sugar naturally.

For people with type 1 diabetes, untreated high blood sugar can lead to a life-threatening condition called diabetic ketoacidosis, or DKA.

When there is no insulin and glucose can't get into cells, your body starts breaking down fat into a fuel called ketones. If ketones build up in your blood, it becomes dangerously acidic. DKA can cause very serious health complications such as fluid building up in the brain, kidney failure, and cardiac arrest.

If your blood sugar is above 240 mg/dL, you should check your urine for ketones, a sign you may be at risk for DKA. You can do this with an at home test, but you also should contact your doctor. If there are ketones in your urine, you should go to the emergency room. Other symptoms of DKA include:

In rare occasions, DKA can occur in people with type 2 diabetes, but the more common complication for people with type 2 is called hyperglycemic hyperosmolar state, or HHS. HHS occurs when blood glucose levels are high for an extended period of time. The extra sugar is passed into the urine, causing the person to urinate frequently and become severely dehydrated, just like with DKA.

For people with type 2 diabetes, blood sugar above 600 mg/dL indicates HHS. Other symptoms include:

These symptoms generally come on slowly, but you should contact your doctor immediately. In the ER, doctors will likely use insulin to lower your blood sugar, as well as give you fluid and electrolytes, to keep your heart, kidneys, muscles, and nerve cells functioning properly.

For people with diabetes, a single instance of high blood sugar is generally not an emergency, as long as it is addressed. Usually, taking an extra dose of insulin will quickly lower your blood sugar back to normal levels. However, if you are on insulin and run out, or have symptoms of DKA or HHS, you should get medical attention right away.

Read the rest here:
How to lower your blood sugar quickly and what to do if it's an emergency - Insider - INSIDER

The use of intensive lifestyle intervention for weight loss in patients with type 2 diabetes has been shown to reduce the overall severity of obstructive sleep apnea (OSA), according to study results published in the American Journal of Respiratory and Critical Care Medicine.

Researchers conducted the longitudinal randomized controlled Sleep AHEAD study (ClinicalTrials.gov Identifier: NCT00194259) an ancillary study of Look AHEAD (Action for Health in Diabetes) enrolled participants from 4 of the 16 Look AHEAD sites.

Investigators sought to establish whether initial benefit of intensive lifestyle intervention for weight loss on OSA severity would be maintained at 10 years. The primary study objective was to determine whether the Look AHEAD intervention was associated with improvements in apnea-hypopnea index (AHI) at 10 years and during the 10-year follow-up. Secondary objectives included determining whether this effect was independent of weight change and whether the intervention had an effect on changing an individuals OSA category.

Primary study inclusion criteria of Look AHEAD (and, thus, of Sleep AHEAD) were being between ages 45 and 7, having a body mass index (BMI) of 25 kg/m2 (or 27 kg/m2 if taking insulin), physician-verified type 2 diabetes, and hemoglobin A1c of <11%. Participants received either intensive lifestyle intervention for weight loss or diabetes support and education (DSE). Of the 264 participants, 38.7% had mild OSA, 35.2% had moderate OSA, and 26.1% had severe OSA at baseline.

At 10 years, polysomnograms were obtained in 54% of those in the intensive lifestyle intervention group and in 48% of those in the DSE group. Mean weight losses in the intensive lifestyle intervention group at 1, 2, 4, and 10 years were 10.70.7 kg, 7.40.7 kg, 5.10.7 kg, and 7.10.8 kg, respectively. These weight losses were all significantly higher than the 1-kg weight loss at 1, 2, and 4 years, and the 3.50.8 kg weight loss at 10 years in the DSE group (P .0001).

The AHI was lower with intensive lifestyle intervention compared with DSE by 9.72.0, 8.02.0, and 7.92.2 events per hour at 1, 2, and 4 years, respectively (P .0004), and by 4.02.5 events per hour at 10 years (P =.109). Changes in AHI over time were associated with the amount of weight loss, baseline AHI, and year of the visit (P <.0001), as well as with the intervention independent of change in weight (P =.01). At 10 years, OSA remission occurred in more participants in the intensive lifestyle intervention compared with participants in DSE group (34.4% vs 22.2%, respectively).

The investigators concluded that although the greater improvement in OSA severity with intensive lifestyle intervention in the initial 4 years was no longer present at the 10-year follow-up and the greater weight loss in the intensive lifestyle intervention group also diminished at 10 years, overall OSA severity decreased across the 10-year study period with intensive lifestyle intervention. This improvement was associated with changes in body weight, greater severity of baseline OSA, and lifestyle intervention unrelated to weight change.

Reference

Kuna ST, Reboussin DM, Strotmeyer ES, et al; for the Sleep AHEAD Research Subgroup of the Look AHEAD Research Group. Effects of weight loss on obstructive sleep apnea severity: 10-year results of the Sleep AHEAD study. Am J Respir Crit Care Med. Published online July 28, 2020. doi:10.1164/rccm.201912-2511OC

Here is the original post:
OSA Severity Reduced in Type 2 Diabetes With Lifestyle Interventions for Weight Loss - Pulmonology Advisor

DUBLIN--(BUSINESS WIRE)--The "Diabetes Assays (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact)" report has been added to ResearchAndMarkets.com's offering.

This market model discusses in detail the impact of COVID-19 on Diabetes Assays market for the year 2020 and beyond.

Companies Mentioned

Hemoglobin (HbA1c) assays are the most commonly used for both initial and confirmatory screening of diabetes across all geographical regions. The American Diabetes Association (ADA) recommends HbA1c tests 2 times per year in patients who are meeting treatment goals and additional testing for patients who are not meeting their treatment goals. Screening may be repeated every three years in patients that have normal test results.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed Diabetes Assays and evolving competitive landscape.

Global, Regional and Country level market specific insights.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Reasons to Buy

The model will enable you to:

For more information about this report visit https://www.researchandmarkets.com/r/awtz02

View post:
Impact of COVID-19 on the Global Diabetes Assays Industry 2020-2030 Featuring Siemens Healthineers, Abbott Labs, Roche, Danaher and Tosoh -...

NEW YORK, Aug. 13, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that an emerging science industry poster has been accepted for presentation at the virtual Association of Diabetes Care and Education Specialists (ADCES) 2020 Annual Conference, which is being held today, August 13, through August 16, 2020.

The poster, entitled, "Impact of Digital Management on Clinical Outcome in Patients with Chronic Conditions: Diabetes and Hypertension," details results from an observational study of 345 participants with hypertensive blood pressure at baseline who utilized the Dario digital therapeutics platform.

Results:

Blood pressure

Diabetes

Notably, the average age of participants in this study was 60.4 years, suggesting that the required use of technology by older individuals does not appear to be a significant barrier to engagement.

The paper concludes, "This observational study of a digital therapeutic platform for chronic disease demonstrates improved blood pressure at three months and glycemic control at six months compared to baseline. These findings suggest that digital therapeutics may help sustain behavioral change and play an important role in the management of diabetes and hypertension."

Erez Raphael, Chief Executive Officer of Dario, stated, "We are excited about these positive results observed across hundreds of patients. We believe that this latest study adds to our growing body of clinical evidence, supporting the use of Dario's platform to produce meaningful health improvements in patients who are trying to better manage their chronic conditions such as hypertension and diabetes. We believe that this information is not only helpful to the physicians who recommend use of our platform, but also to institutions like payers and self-insured employers who benefit from healthier members and employees in the form of reduced medical expenses. This value proposition is an important tool for attracting new clients in our Business-to-Business-to-Consumer (B2B2C) channel."

About DarioHealth Corp.

DarioHealth Corp. (Nasdaq: DRIO) is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, we empower individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Our cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDariomobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. To learn more about DarioHealth and its digital health solutions, visithttp://dariohealth.com

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue"are intended to identify forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses its belief that the study adds to its growing body of clinical evidence, supporting the use of Dario's platform to produce meaningful health improvements in patients who are trying to better manage their chronic conditions such as hypertension and diabetes, its belief that the information is not only helpful to the physicians who recommend use of its platform, but also to institutions like payers and self-insured employers who benefit from healthier members and employees in the form of reduced medical expenses and that the value proposition is an important tool for attracting new clients in the its B2B2C channel.Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contact:Claudia LeviContent & Communications Manager[emailprotected]+1-347-767-4220

Media Inquiries:Investor Relations Contact:Chuck Padala[emailprotected]+1 646-627-8390

SOURCE DarioHealth Corp.

https://www.dariohealth.com/

View original post here:
DarioHealth Announces Poster Presentation at the Virtual Association of Diabetes Care and Education Specialists 2020 Annual Conference - PRNewswire

InForGrowth Market Research offers a most recent distributed report on Global Diabetes Drug industry examination and figure 2019-2025 conveying key bits of knowledge and giving an upper hand to customers through a point by point report. The report contains XX pages which profoundly displays on current market investigation situation, up and coming just as future chances, income development, evaluating and gainfulness. The Global pandemic of COVID19 calls for redefining of business strategies. This Diabetes Drug Market report includes the impact analysis necessary for the same

Download Sample Table of Content PDF of COVID-19/CoronaVirus Impact Analysis of Diabetes Drug Market 2020. https://inforgrowth.com/CovidImpact-Request/3081936/diabetes-drug-industry-market

Worldwide Diabetes Drug Market inspect reports consolidate market designs nuances, genuine scene, feature assessment, cost structure, capability, bargains, net advantage, and movement and measuring of business.

Major Key players covered in this report:Eli Lilly., Mylan., Johnson & Johnson., NovoNordisk., Merck., Boehringer Ingelheim., Wockhardt., Bristol Myers Squibb., GlaxoSmithKline PLC., Exir., Julphar., Abbott Laboratories., SEDICO., AstraZeneca., Sanofi., Pfizer., Biocon., Novartis, Astellas.

Diabetes Drug Market Potential

The overall market is set up for energetic advancement with progressively moving of various gathering methodology to more affordable objectives in rising economies. Another factor booked to altogether bolster the market is fused programming game plans disposing of the prerequisite for different models and thing survey concerns.Premium Insights on Diabetes Drug Market 2020 with Market Players Positioning; Download Sample Copy: https://inforgrowth.com/sample-request/3081936/diabetes-drug-industry-market

The Worldwide Market forGlobal Diabetes Drug marketis relied upon to develop at a CAGR of generally xx% throughout the following five years, will arrive at xx million US$ in 2026, from xx million US$ in 2019, as per another research.

This report focuses around the Diabetes Drug Market in the worldwide market, particularly in North America, Europe and Asia-Pacific, South America, Middle East, and Africa. This Diabetes Drug Market report sorts the market dependent on the manufacturer, region, type, and application.

Major Classifications of Diabetes Drug Market:

By Product Type: Sulphonylureas, Biguanides, Meglitinides, Thiazolidinediones, Alpha-glucosidase Inhibitors, DPP-4 Inhibitors, SGLT-2 Inhibitors

By Applications: Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes, Impaired Glucose Tolerance and Impaired Fasting Glycaemia

The study objectives of Diabetes Drug Market Report are:

Regional Analysis of Diabetes Drug Market:

The report additionally provides a local examination of the market with a high focus on showcase development, development rate, and development potential. The research report calculates marketplace length estimation to analyze investment possibilities and destiny growth. The key players and distinctive affecting components are examined completely on this report.

Get Chance of 20% Extra Discount, If your Company is Listed in Above Key Players List https://inforgrowth.com/discount/3081936/diabetes-drug-industry-market

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898Website: http://www.inforgrowth.com

Originally posted here:
Diabetes Drug Market 2020: Potential Growth, Challenges, and Know the Companies List Could Potentially Benefit or Loose out From the Impact of...

Type 2 diabetes could be caused by the body not producing enough of the hormone insulin, or the body not reacting to insulin.

Without enough of the hormone, the body struggled to convert sugar in the blood into useable energy.

It's crucial that if you think you may have diabetes, you speak to a doctor as soon as possible.

You may be at risk of the condition if you notice some changes to the skin on your feet.

READ MORE: Type 2 diabetes symptoms - the major sign in your thighs

"Constantly feeling thirsty, weeing all the time and feeling really tired; these are all symptoms that should lead us to think about diabetes," warned Benenden Health's society matron, Cheryl Lythgoe.

She told Express Health: "However, when it comes to diabetes, there are many other symptoms that should be getting our attention too.

"For example, if you struggle with one infection after another - a wound infection that wont settle or a fungal infection such as thrush or athlete's foot, for example this could be a symptom of diabetes.

"All of these signs and symptoms could be an indicator of diabetes and would require a discussion and some testing with your GP."

Many people may have diabetes without even knowing it, because the signs and symptoms dont necessarily make you feel unwell.

Common diabetes symptoms include having cuts or wounds that take longer to heal, having an unquenchable thirst, and passing more urine than normal.

You should speak to a doctor if youre worried about the warning signs or symptoms of diabetes, or if you think you may be at risk.

Diagnosing the condition early is very important, because patients are more at risk of some deadly complications, including heart disease and strokes.

See the original post:
Diabetes type 2 warning - do your feet look like this? The sore patches of skin - Express

Columbia researchers have uncovered an array of new genes that cause stillbirth, significantly increasing the understanding of the condition's genetic foundations. The findings suggest that genetic analysis could be used to counsel parents who have previously experienced stillbirth and to unlock new human biology.

Using both standard and advanced analysis techniques, the team led by David Goldstein, PhD, and Ronald Wapner, MD, of Columbia University Vagelos College of Physicians and Surgeons (VP&S) identified the likely genetic cause of stillbirth in about one of every 10 cases studied.

"This study shows that careful genetic analyses can often identify the precise genetic causes of stillbirth and demonstrates the importance of diagnostic sequencing in all cases of unexplained stillbirth," says Goldstein, director of the Institute for Genomic Medicine at Columbia University Irving Medical Center. "Of equal importance, the work highlights how little we currently understand about the biology of stillbirth and the role that genomic analysis can play in helping us understand it."

The study was published online today in the New England Journal of Medicine by the Columbia team. Kate Stanley, MS, a research associate in the Goldstein lab, and Jessica Giordano, MS, a research genetic counselor in the reproductive genetics division of the Department of Obstetrics & Gynecology at VP&S, were co-first authors of the study.Presumed Genetic Underpinning, but Few Studies

Stillbirth (the in utero death of a fetus after 20 weeks' gestation) occurs in approximately one in 100 pregnancies and is about 10 times more common than sudden infant death syndrome.

But in the majority of cases, the cause of stillbirth is unknown. Some have been linked to maternal medical conditions such as infection and preeclampsia; 10% to 20% are attributed to large and easily detectable chromosomal abnormalities. Only a few genes have been implicated.

"Unlike postnatal childhood conditions that are presumed to be strongly genetic, stillbirth had yet to be systematically analyzed with modern genome sequencing approaches," says Goldstein.

"All too often, we have no explanation to give parents who experience a stillbirth," says Wapner, professor of obstetrics & gynecology. "Not only are they devastated, they're often left to wonder if it's something they did wrong or if it might happen again."

Genomic Sequencing Plus New Bioinformatic Analyses Find Hidden Genetic Causes

Genomic sequencing has been particularly useful in diagnosing otherwise unexplained childhood disorders and fetal structural defects, and the Columbia team used it for the first time to search for genetic variants that cause stillbirth.

The researchers sequenced all protein-encoding genes--where most known disease-causing genetic variants occur--from 246 stillborn fetuses and deployed new statistical analyses to identify the genetic mutations that caused the death of the fetus.

The combination of traditional sequencing and new analytical techniques revealed small changes in 13 genes that caused fetal death; six of the genes had not been previously linked to stillbirth.

"Although these are small changes in only a single site in the genome, they are, in effect, genomic sledgehammers that either dramatically change or knock out essential genes and appear responsible on their own for fetal demise," Goldstein says.

The small genetic changes explained 8.5% of the stillbirths in the study. When combined with a previous analysis of larger genomic alterations in this group, the researchers determined that 18% of the stillbirths had a known genetic cause.

The analysis also showed a critical difference compared with the study of postnatal genetic conditions.

"Interestingly, some of the changes we found in genes known to cause postnatal diseases and conditions appeared to have more profound effects than the mutations linked to postnatal disease," Goldstein adds.

Clinical Implications

Currently, the analyses required to find causal genetic causes of a stillbirth can be conducted in only a few academic medical centers.

But eventually the findings from this study--and future studies--will help physicians counsel parents and guide clinical care.

"To a woman who's just had a stillbirth, specific knowledge about the cause is critical," Wapner says. "They often blame themselves and some decide not to have any more children."

If the stillbirth can be attributed to a genetic mutation that has only occurred in the fetus, not in the parents, the same problem is unlikely to occur in future pregnancies.

"That knowledge would change the way we would provide care," Wapner says, "and facilitate closure and bereavement for families."

Unlocking New Human BiologyMost genetic diagnostic studies focus on genes already known to cause disease. Because stillbirth has been understudied, however, the team wanted to test whether genetic changes in genes not currently linked to disease contribute to stillbirth.

For this assessment, the researchers used a bioinformatic tool pioneered by the Goldstein lab that focuses on genes that are under the strongest natural selection in the human population--known as "intolerant" genes. The lab team showed that at least 5% of stillbirths are likely explained by mutations in intolerant genes that are not currently linked to any known human disease.

"These novel disease genes appear to be critical for early human development, and the only way to discover them is through the analysis of fetuses that do not develop," Goldstein says.

"We're opening up new frontiers in biology and the more we understand about basic human development, the more we can potentially intervene."

Reference: Stanley et al. (2020).Causal Genetic Variants in Stillbirth. The New England Journal of Medicine.DOI: 10.1056/NEJMoa1908753.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read more here:
Genetic Variants and the Biology of Stillbirth - Technology Networks

Genetic variation combined with elevated aggression scores may predict childhood suicidal thoughts, while suicidal thoughts in childhood may point to young adult depression, according to data published in the Journal of Affective Disorders.

Researchers at the University of Pennsylvania wanted to determine if suicidal ideation in childhood was associated with genes indicative of suicidal ideation in adults. They also wanted to determine if aggression played a role in childhood suicidal thoughts.

A psychiatric disorder is present in more than 90% of adult suicides, according to the investigators, and aggression is associated with increased suicidal behaviors in both children and adults. Uncovering the role of childhood suicidal behavior on the development of psychiatric disorders later in life, as well as the influence of aggression, could help with suicide prevention efforts.

A total of 478 participants aged 8 through 18 years enrolled in the study and received ongoing assessment until age 19. Using multiple behavior assessment tools, researchers found that 25.9% of participants reported suicidal thoughts during 1 or more visits. These thoughts occurred for the first time at a median age of 13 years (mean age, 12.72.9 years; range, 8-18 years). Of the 17 children that attempted suicide, 10 reported aggression. Results of a Cox Survival analysis demonstrated a significant association between childhood aggression and suicide attempts.

To determine the role of genetics in the onset of suicidal thoughts, investigators tested specific haplotypes within ANKK1-DRD2 and HTR2C as potential predictors of suicidal thoughts and behaviors. Structural equation model results demonstrated that 3 single nucleotide polymorphisms (SNPs) within the HTR2C gene, 1 SNP in the ANKK1 gene, and 2 haplotypes AAAC in the ANKK1-DRD2 complex and the CCC haplotype in the HTR2C gene were significantly associated with suicidal ideation in childhood.

Limitations of the study include the relatively small sample size and the use of assessments conducted between 1990 and 2010, which does not account for the rise in suicide rates over the past decade.

Using genetic sequencing, researchers found specific haplotypes within ANKK1-

DRD2 and HTR2C genes are associated with either risk or resilience to developing suicidal

thoughts in childhood, depending on the individuals genetic background. Determining overall levels of aggression further helps determine which children will develop suicidal thoughts.

These observations have the potential to provide a framework for precision medicine that utilizes both genetic variation and phenotypic markers for early intervention and treatment, the researchers concluded.

Reference

Hill SY, Jones BL, Haas GL. Suicidal ideation and aggression in childhood, genetic variation and young adult depression [published online July 24, 2020]. J Affect Disord. doi: 10.1016/j.jad.2020.07.049

Read more here:
Evaluating the Role of Genetics in Pediatric Suicidal Ideation and Aggression - Psychiatry Advisor

[This unedited press release is made available courtesy of Gamasutra and its partnership with notable game PR-related resource GamesPress.]

14th August - Zurich, Switzerland - Indie team Stray Fawn Studio (Nimbatus) today announced that their genetic survival sim Niche will be coming to Nintendo Switch! It will release on the 3rd September and pre-orders with a 10% discount are available now. The initial Steam release was met with great player feedback and currently has over 2700 users reviews, ranking the game as very positive.

Niche is a colourful genetic survival game about selectively breeding and evolving an adorable species of creatures to keep them alive against all odds, such as hungry predators, climate change and sickness. Combining turn-based strategies with simulation and roguelike elements, the game provides tons of different approaches to survive in the harsh environment.

Stray Fawn Studios game designer Philomena Schwab always had a strong affinity for biology and even struggled for a time to decide whether she wanted to pursue that field or game design. As a result, she decided to create Niche, a game about population genetics with a mating system based on real gene science, featuring mutation, dominant/recessive/codominant heredity and much more.

With a genetics system based on real DNA, the PC version of the game is currently also free for teachers to use in classrooms and is used by over 300 biology teachers for their studies.

Nintendo Switch review codes are available via [emailprotected] for editorial outlets.

Game features:

About Stray Fawn Studio

Stray Fawn Studio is an indie team from Zurich, Switzerland led by Micha Stettler and Philomena Schwab, with a focus on procedural world generation and creative freedom of the player.

Their first game Niche was initially released on Steam in September 2016, and since then

Stray Fawn Studio has delivered two other games, Nimbatus and Retimed.

The studio is now working on the Switch release for Niche, and a super-duper special unannounced project.

Continue reading here:
Genetics survival game Niche comes to Switch on the 3rd September - Gamasutra

The information below has been supplied by dairy marketers and other industry organizations. It has not been edited, verified or endorsed by Hoards Dairyman.

Following the release of the August 2020 genetic evaluations, bulls from New Generation Genetics proven and genomic bulls ranked at or near the top for Milk, Components, Type, Udder Composite, Mobility, Fertility, DPR, Productive Life, NM$, PPR, & Profit.

54BS557 BMG Lust GET LUCKY *TM continues to lead the way as the #1 proven bull for milk, fat, and protein. Get lucky is also the #1 Proven bull for PPR at 189. His milk is +2594, +58f and +57p.

54BS558 Hilltop Acres B DAREDEVIL ET *TM is the breeds type leader with daughters impressing on farms and in the show ring. He continues as the #1 proven type bull at +1.0 with an udder composite now at +1.16.

54BS564 Jo-Lane Dario HAMPTON ET *TM dominates in health traits, profit, and fertility. After completing his 1st crop he ranks #4 for productive life at +5.2 with a +1.7 DPR. He is the new #5 proven Net Merit bull at $327 and #5 SCR ranking at +1.5.

54BS561 Hilltop Acres BV JESSE ET *TM is a new graduate at +624 milk, +0.6 type, +0.71 UDC, +0.7 DPR, and positive SCR. He offers an impressive outcross pedigree, phenomenal udders, and great dairy strength.

54BS601 La Rainbow Sweet SALSA ETV *TM Is the #1 G-type bull at +1.1 type and +1425 milk. This Genomic Gem is a LUCKY CARL brother to SILVER, giving him an impressive pedigree to back his historic numbers.

54BS604 La Rainbow Sweet SPARK *NP is a new genomic polled bull at +750 milk, +0.8 type, and +1.18 UDC, earning him #1 genomic polled status in these three categories.

196BS55878 Portmann BS Bays JONMAR *TM is an exciting new offering from Swissgenetics. He is the #8 G-PPR bull at 182 and #5 genomic Net Merit bull at $466. He is also +1158 milk, +43 fat, +40 protein, +0.79 UDC, and +2.1 DPR.

We also offer the CHAMPIONS COLLECTION elite sire lineup including 54BS600 WINRITE, 54BS602 FIRST CHOICE, 54BS539 RICHARD, 54BS581 RASTA, 54BS568 FAST & FURIOUS, and 54BS548 WINNING FORMULA.

New Generation Genetics offers the most comprehensive Brown Swiss Sires portfolio in the U.S. For further information call 920-568-0554, visit our Facebook page http://www.facebook.com/newgenerationgenetics, email info@brownswiss.com or visit http://www.brownswiss.com.

See the article here:
New Generation Genetics Bulls Lead the Way Following the Genetic Evaluations in August - Hoard's Dairyman

Baylor Genetics and Rice University form partnership to create a first-of-its-kind solution for the university to resume in-person classes for the fall semester despite the COVID-19 pandemic

HOUSTON, Aug. 13, 2020 /PRNewswire/ --Baylor Genetics, a clinical diagnostics laboratory known for genetic testing and precision medicine, and Rice University, a private, comprehensive research university located in Houston, Texas, have partnered together to create a first-of-its-kind, total turnkey solution for the university to resume in-person classes for the fall semester despite the COVID-19 pandemic.

"For Baylor Genetics and Rice University, this partnership represents a moon-shot opportunity to benefit students, faculty, and staff," stated Kengo Takishima, President and Chief Executive Officer at Baylor Genetics. "It is imperative families have peace of mind as they send their children to college and we've set an aggressive goal of serving as a blueprint for other academic institutionsand, more broadly, society."

Many universities nationwide have been strongly impacted by the pandemic and have announced changes to the fall semester. One of the major changes is universities going fully online for the semester. Fortunately, Rice has been able to overcome many challenges brought on by COVID-19 thanks to its partnership with Baylor Genetics.

"In terms of learning online, I found that it wasn't that intuitive and effective for my own learning style. In addition to that, it is my senior year and I wanted to get one last taste of the community that I have come to grow and love here," said Victor Nguyen, a senior at Rice University, in an interviewreleased by the university. "Being on campus again feels a little bit more of what we are used to, even though we live in a new reality. It's closer to normal so it's exactly what we were hoping for."

This partnership entails Baylor Genetics providing support for temperature checks, on-campus sample collection and transport logistics, processing of samples, and customized results reporting for individuals via email. Nearly 60,000 screening tests will be performed by Baylor Genetics with a turnaround time of 48 hours or less.

Story continues

In addition to large-scale surveillance testing, the partnership includes population management reporting. This custom reporting system delivers population data to assist policymakers at Rice with managing the campus community and by aiding in intelligent decision making.

"Testing by itself is not enough," said Kevin Kirby, Rice University's Vice President for Administration."What matters is how we use that information to act quickly to isolate, treat, contact trace, and quarantine those affected. A systematic approach is the best practice for creating an environment that will mitigate the spread of COVID-19."

In addition, data tracking will provide the university with specific trends and infection rates on buildings, facilities, and housing throughout the campus. This innovative approach is part of Rice's strategy to prevent cross-contamination and ensure the safety of its faculty, students, and staff. There are plans to extend the partnership with symptomatic testing in the near future.

"This opportunity is a chance to demonstrate that we can operate safely in such a difficult time," said Chad Shaw, Ph.D., Sr. Director of the Baylor Genetics Innovation Lab, Adjunct Professor of Statistics at Rice University, and Professor in the Department of Molecular and Human Genetics at Baylor College of Medicine, "As a Houstonian and a member of both the Baylor and Rice faculty, I am excited by the opportunity to serve my community to find a thoughtful and creative way to overcome the COVID challenge. It takes commitment, grit, and a team effort."

The program began the week of Aug. 3 with college staff, graduate students, and orientation coordinators. For students, testing is broken down into three phases and will begin Aug. 15. There will be no charge to faculty, studentsor staff for the on-campus testing.

For members of the Rice community that are confirmed positive for the coronavirus (SARS-CoV-2), Rice will follow the Centers for Disease Control and Prevention contact-tracing protocols to identify others who have had significant contact with those tested positive.

Baylor Genetics' test for COVID-19 has one of the highest sensitivity (true positive rate) and specificity (true negative rate) rates for identifying active coronavirus infection. All precautions, policies, and guidelines have been put in place with one goal in mind continue education in the safest, most effective way possible.

Media Contact:Jamie LimEmail: pr@baylorgenetics.com

Related Images

on-campus-collection-site-at-rice.jpg On-campus collection site at Rice University

Related Links

COVID-19 Testing at Baylor Genetics

Return to Rice

View original content to download multimedia:http://www.prnewswire.com/news-releases/baylor-genetics-and-rice-university-form-covid-19-screening-partnership-for-the-fall-semester-partnership-aims-for-moon-shot-48-hours-or-less-turnaround-for-test-results-301111805.html

SOURCE Baylor Genetics

See original here:
Baylor Genetics and Rice University Form COVID-19 Screening Partnership for the Fall Semester; Partnership Aims for 'Moon-Shot' 48-Hours-or-Less...

Image: Breast cancer cell. Credit: Anne Weston, Francis Crick Institute.

UK scientists have discovered three new genetic changes that increase the risk of breast cancer in men, in the worlds largest genetic study of the causes of male breast cancer to date.

Researchers, largely funded by Breast Cancer Now, identified three common variations in DNA that predispose men to developing breast cancer, bringing the total known number to five.

All three genetic variants are known to be linked to female breast cancer but scientists at The Institute of Cancer Research, London, and Queens University Belfast found the changes to have a greater effect on breast cancer risk in men than in women.

The study involved 1,380 men with breast cancer, primarily from the Breast Cancer Now Male Breast Cancer Study based at The Institute of Cancer Research (ICR). The team found that three genetic changes, called rs9371545, rs554219 and rs78540526, increased the risk of developing breast cancer in men by approximately 47, 45 and 61 per cent respectively.

The researchers then analysed over 170 SNPs known to affect risk in women, finding significant overlap in the genetic risk factors for the disease in men. The results suggest male and female breast cancer may have a very similar genetic basis a discovery which could in future lead to new preventive treatments for men and women.

The study also found that men at the highest genetic risk were almost four times more likely to develop breast cancer than those at lowest risk.

Breast Cancer Now described the discovery as a major step forward in our understanding of male breast cancer, calling for greater awareness of the disease in men and for research into the shared genetic causes of male breast cancer and the most common form in women (ER+), to develop risk-reducing drugs and other interventions to prevent more cases among those at increased risk.

The study was funded by Breast Cancer Now and Queens University Belfast, and is published in the Journal of the National Cancer Institute.

While breast cancer in men is very rare, around 370 men are diagnosed with the disease every year in the UK, and around 80 men lose their lives each year.

There are a number of different treatments for breast cancer in men depending on the features of the tumour, including surgery, hormone therapy, radiotherapy, chemotherapy and targeted drugs all of which were first developed to treat the disease in women.

More than 95 per cent of all breast cancers in men are oestrogen receptor (ER) positive compared to up to 80 per cent of cases in women meaning that they contain proteins called oestrogen receptors and can be stimulated to grow by the hormone.

Men with a strong family history of breast cancer among female relatives are known to be at greater risk, and around 10 per cent of male cases are caused by mutations in the BRCA2 gene. But the exact causes of the disease in men are not yet understood, and, for years, there has been considerable debate about whether male and female breast cancer are distinct from one another.

While mutations in genes such as BRCA2 can increase the risk of breast cancer by a great deal, these faults are relatively rare and major research has shown that single-letter changes to our DNA code (called Single Nucleotide Polymorphisms or SNPs) also influence cancer risk.

With up to 15 million places where SNPs can exist across our genome, these changes are relatively common.

In a major new genetic analysis pooling data from multiple studies worldwide, researchers led by Dr Nick Orr at the Breast Cancer Now Research Centre at The Institute of Cancer Research (ICR) and at Queens University Belfast compared the genomes of 1,380 men with breast cancer to 3,620 men without.

The scientists discovered three new SNPs that were significantly associated with an increased risk of breast cancer in men: one on chromosome 6 (rs9371545) and two on chromosome 11 (rs554219 and rs78540526).

The researchers then investigated the extent of the shared genetic causes of the disease in men and women by evaluating 172 regions in the genome linked to female breast cancer, for an association with male breast cancer.

The team found a strong correlation between the genetic risk factors of male and female breast cancer, with 20 per cent of SNPs that influence (increase or decrease) the risk of breast cancer in women also having an effect on male breast cancer risk.

The study also observed some important differences, with some SNPs carrying a greater increase in risk for women than for men or vice versa, and some SNPs also changing the risk in opposite directions for men than for women.

We've lost many vital research hours to the coronavirus crisis but the need for our work continues to grow. Please help uskick-startour research to make up for lost time in discovering smarter, kinder and more effective cancer treatments, andto ensure cancer patients don't get left behind.

Read more

Having identified this overlap, the researchers then investigated how well a DNA test (313 SNP risk score), which was designed to estimate breast cancer risk in women, worked for men.

They found there was nearly a four-fold increase in risk between men in the highest genetic risk category and those in the lowest (OR= 3.86), and that the distribution of cases across risk categories was similar to that observed in women.

The findings add to the major discovery in 2012 from the Breast Cancer Now Male Breast Cancer Studyby the same authors, that a single change in the genetic code of a gene called RAD51B can increase the risk of breast cancer in men by up to 50 per cent.

It is hoped that the discovery of new locations in the genome linked to male breast cancer could now enable scientists to identify the biological mechanisms that cause the disease to develop in men, and could ultimately lead to the development of new preventive drugs for those at high risk.

While further research would be needed, the authors also suggest the findings could in future help to develop more precise risk testing for men carrying BRCA2 mutations, enabling them to understand whether they are at additional or lower risk due to other genetic changes, which could help guide decisions around any risk-reducing steps.

Lead author Dr Nick Orr, who led the research at the ICR, and the Patrick G. Johnston Centre for Cancer Research at Queens University Belfast, said:

There has been much debate about whether breast cancers in women and men are distinct from one another. Our study has shown, for the first time, that the genetic factors influencing susceptibility to male breast cancer and the most common type of female breast cancer are much more alike than they are different.

Our findings suggest that the underlying biology that affects how breast cancer develops and grows are probably similar in men and women. This means that advances in prevention and treatment for the disease may be of benefit to all patients, irrespective of their gender.

Dr Simon Vincent, Director of Research, Services and Influencing at Breast Cancer Now, which funded the study, said:

This study, which shows more of a similarity between the genetic causes of the disease in men and women than previously thought, is a major step forward. Our knowledge of breast cancer in men is limited, because male breast cancer is rare which makes it difficult to collect enough tissue or blood samples to research and understand the disease. Research like this is critical to improving our understanding of the disease in men and we hope the Breast Cancer Now Male Breast Cancer Study will continue advancing our knowledge.

We now look forward to further research into the shared genetic causes of male breast cancer which could lead to developing risk reducing treatments and interventions to help prevent more cases among those at increased risk in the future.

The Breast Cancer Now Male Breast Cancer Study is the largest collection of DNA and tumour samples from men with breast cancer in the world, with over 1,000 men who have been diagnosed participating, as well as over 1,000 men without breast cancer. Based at the ICR, the study was established in 2008 to pinpoint the genetic, environmental and lifestyle causes of breast cancer in men.

Jo Tridgells husband John died in January 2017 after being diagnosed with breast cancer in November 2015. John took part in several research projects, including the National Male Breast Cancer Study led by the ICR. Commenting on the new research, Jo said:

When my husband John was going through treatment, it was always a question mark for me whether breast cancer in men warranted different drugs than that in women. This new study shows that the disease is genetically similar irrespective of your sex, so that feels like a real breakthrough knowing that treatment courses could be the same. Any research that helps us to understand how breast cancer risk can be monitored and the disease prevented in future is of vital importance to families like ours.

Read more here:
Scientists discover three new genetic variants linked to male breast cancer - The Institute of Cancer Research

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the animal genetics market and it is poised to grow by USD 1.79 billion during 2020-2024, progressing at a CAGR of 7% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Free Sample Report on COVID-19 Impact

Frequently Asked Questions-

The market is concentrated, and the degree of concentration will accelerate during the forecast period. Animal Genetics Inc., AquaGen AS, Aviagen Group, Coperatie Koninklijke CRV u.a., Genetic Veterinary Sciences Inc., Genus Plc, Hendrix Genetics BV, Neogen Corp., Topigs Norsvin, and Zoetis Inc. are some of the major market participants. To make most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Animal Genetics Market 2020-2024: Segmentation

Animal Genetics Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40040

Animal Genetics Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our animal genetics market report covers the following areas:

This study identifies the increase in consumption of animal-derived food products as one of the prime reasons driving the animal genetics market growth during the next few years.

Animal Genetics Market 2020-2024: Vendor Analysis

We provide a detailed analysis of vendors operating in the animal genetics market, including some of the vendors such as Animal Genetics Inc., AquaGen AS, Aviagen Group, Coperatie Koninklijke CRV u.a., Genetic Veterinary Sciences Inc., Genus Plc, Hendrix Genetics BV, Neogen Corp., Topigs Norsvin, and Zoetis Inc. Backed with competitive intelligence and benchmarking, our research reports on the animal genetics market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Animal Genetics Market 2020-2024: Key Highlights

Table of Contents:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

PART 04: MARKET SIZING

PART 05: FIVE FORCES ANALYSIS

PART 06: MARKET SEGMENTATION BY SOLUTION

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

PART 13: VENDOR ANALYSIS

PART 14: APPENDIX

PART 15: EXPLORE TECHNAVIO

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

View post:
Insights on the Global Animal Genetics Market 2020-2024 | COVID-19 Analysis, Drivers, Restraints, Opportunities and Threats | Technavio - Business...

Findings and methods developed can be used to screen large populations and high-risk individuals at a cost less than Rs 5000, according to the release

Findings of the first-ever research capturing the polygenic risk score for South Asia populations for coronary artery disease were recently published in the Journal of the American College of Cardiology (JACC).

Conducted by MedGenome Labs, in collaboration with researchers from Broad Institute of MIT and Harvard; Massachusetts General Hospital, Boston; Narayana Health, Bangalore; Eternal Hospital, Jaipur; Madras Medical Mission, Chennai; KMCH, Coimbatore and a few other institutes, the study on Indian population validates a novel CAD-PRS (coronary artery disease-genome-wide polygenic risk score) to precisely predict the risk of developing a coronary artery disease/myocardial infarction (MI) using a persons genetic makeup.

Knowing the polygenic risk is important to individuals with a family history of CAD, hypertension, diabetes, high cholesterol level, smoking habits, alcohol consumption, stressful lifestyle, as CAD results from a combination of these factors. A poor lifestyle and high polygenic risk could be a fatal combination and may result in early-onset CAD.

Such findings and methods developed can be used to screen large populations and high-risk individuals at a cost less than Rs 5000.

Looking at all the available scientific evidence and our study results we are convinced that there exists a good opportunity to combine both clinical and genetic risks (polygenicrisk score based) and significantly improve the primary prevention of coronary artery disease (CAD). We firmly believe that incorporatingvalidated genetic risk scores would help in better stratification of high-risk individuals if implemented at population level,said Dr Vedam Ramprasad, CEO, MedGenome Labs.

This unique study is based on the principle of Genome-wide Polygenic Risk Score (PRS) which usesa genome-wideanalysis of an individual to quantify the risk of developing heart disease.

It was conducted on the south Asian population in 1800 confirmed CAD cases and 1163 control samples from five centres across the country with a median age between 54 and 55 years. The findings of this study have helped develop a CAD PRS that integrates information from millions of sites of common DNA variation into a single metric that can be calculated from birth and validate a scalable polygenic score framework in India. This finding lays the scientific and operational foundation for clinical implementation not just for CAD but for other diseases.

CAD PRS is a powerful genetic predictor that can be used to identify individuals at increased risk for CAD. It provides a quantified risk score based on ones genetic makeup and predicts a patients risk for having an acute coronary event, such as a heart attack, before symptoms appear. CAD PRS is an important new risk factor to help physicians stratify high-risk patients and better guide treatment decisions and lifestyle interventions, said Dr Sekar Kathiresan, CEO, Verve Therapeutics and Professor of Medicine, Harvard Medical School, Cardiology Division, Massachusetts General Hospital.

According to a research paper published in theJournal of Genetics, the estimated prevalence of CAD disease in India is about 10.5 per cent of the population which extrapolates to a burden of about 32 million affected individuals. Over and above, the incidence of cardiac disorders has increased from 2 per cent to 10.5 per cent of the urban population in the past few years and early age of onset is a new countrywide trend.

South Asians no matter where they stay in India or any other country always have higher cases of CAD than Caucasians. Even if our body structure is much leaner, smaller and thus comparatively lower food consumed compared to Caucasians, we still end up with CAD. So, it can be considered that South Asians have some genetic issue that is causing high CAD cases and hence we need to identify these genetic factors so that we are able to manage the disease in our population, said Dr Ajit Mullasari, Director, Adult Cardiology, Madras Medical Mission.

The virtual press conference and announcement was also supported by several eminent cardiologists from across the country Dr Ramesh Seshadri, Dr Julius Punnen, Dr Varun Shetty, Dr Bagirath Raghuraman from Narayana Institute of Cardiac Science, Bangalore, Dr.Pradeep Narayan, RTIIS, Kolkata, Dr Rajendra N.S, Narayana Hospital, Mysore and Dr Rajeev Gupta, EHCC Jaipur.

Excerpt from:
Experts develop genetic risk score to predict heart disease in South Asia - Express Healthcare

The study is the first comprehensive attempt to determine the genetic relatedness of the Gujjars and Ladakhis to populations within India and elsewhere in the world

The Union Territories of Jammu and Kashmir (J&K) and Ladakh in North India, withtheir wide variety of landscape,are a congruence of several languages and cultural practices. The region is believed to have served as a corridor for ancient human migrations between the Indian subcontinent and North-East Asia, Eurasia and Africa.

The populations in the region offer a unique opportunity to investigate the past anthropological and demographic events which might have shaped the extant human population diversity. In a new study, scientists at the Department of Biotechnologys Centre for DNA Fingerprinting and Diagnostics (DBT-CDFD) have sought to decipher the genetic diversity encompassed by Gujjars from the Jammu region of J&K and the Ladakhi populations.

A previous study had found that the two communities Gujjars and Ladakhis exhibited lower genetic affinity towards other populations in their geographical proximity. To better understand the genetic diversity in these populations, a battery of DNA markers located on autosomes, Y-chromosome and the mitochondrial genome were employed.

The principal coordinate and cluster analysis based on autosomal DNA markers indicated Gujjars and Ladakhis were genetically distant to each other as well as to other reference populations of India, which was in concordance with Y-chromosomal analysis.

The genetic affinity of Gujjars in the Jammu region to Pashtuns in the Baghlans and Kunduz provinces of Afghanistan and Pashtuns and Sindhis in Pakistan indicated their past genetic relatedness and a common ancestry. On the other hand, Ladakhis were found to be genetically close to Chinese (Uighurs and Han) and Nepalese (Magar) populations, which might be due to their close geographic proximity.

Y-haplogroup (which represent a group of individuals who have inherited a common set of markers)-based studies suggested that the Gujjars are less diverse as compared to Ladakhis. The presence of many rare haplogroups in Ladakhis portrays rich accumulation of male-mediated contribution in the past.

The mitochondrial DNA analysis supported the findings that the Gujjars are less genetically diverse as compared to Ladakhis, which perhaps may be due to the endogamous cultural practices in this group (where they marry within a specific community or caste or group). The Y-chromosomal and mitochondrial analysis showed higher genetic differentiation among males than females indicating patrilocality among these populations.

The present study is the first comprehensive attempt to determine the genetic relatedness of the Gujjars and Ladakhis to populations within India and elsewhere in the world and would help in gaining deeper insights into genetic diversity and demographic settlement in this part of the world.

The researchers, Mugdha Singh, Anujit Sarkar, Devinder Kumar and Madhusudan R Nandineni, have published a paper in Scientific Reports titled `The genetic affinities of Gujjar and Ladakhi populations of India. (India Science Wire)

We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.

Continued here:
New study sheds light on genetic affinities of Gujjars and Ladakhis - Down To Earth Magazine